IMA203CD8 Product
Phase 2Biologic
IMA203CD8 Product is one of 32 biologic programs targeting Refractory Solid Tumors. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Refractory Solid Tumors
#DrugCompanyPhaseTrials
1Camptosar
PfizerPhase 2
Votrient
NovartisPhase 2
Oncovin
Eli LillyPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Ibrance
PfizerPhase 2
Tecentriq
RochePhase 2
Plaquenil
Jazz PharmaceuticalsPhase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMA203CD8 Product. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmatics US, Inc.